Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Theme
Learn more about COPD to overcome the obstacle: Breathe better, Live more
- COPD Congress 2017

About Conference

Allied academies invites all the participants across the globe to attend the “5th International Congress on Chronic Obstructive Pulmonary Disease” slated on November 06-07, 2017 in Vienna, Austria.
Dates: November 06-07, 2017
Venue: Vienna, Austria.
Theme: Learn more about COPD to overcome the obstacle: Breathe better, Live more

Allied Academies was founded by Jim and JoAnn Carland and the headquarters is located in North Carolina in United States of America. It conducts several academic conferences each year in different locations with internet participation possibilities for those who are physically unable to attend the conferences. Conference registrants are eligible for the Accelerated Journal Review. To provide you with maximum outlets for your research, Allied Business Academies holds joint meetings of all its member academies. In 1994 they launched the Journal of the International Academy of Case Studies, which has become a leader in publishing classroom teaching cases in business.

Why to attend COPD Congress 2017?
COPD Congress 2017 gives an exciting opportunity to meet with like minded individuals and industry peers. Congress unite individuals from all different geographical areas who share a common discipline or field. Congress gives you the opportunity to converse with these individuals one-on-one about what they are really going after, and they may even give you guidance on how to enhance your own particular work. At conference you have the opportunity to get feedback on your work from individuals who have never seen it before and may provide new insight. Briefly it is an invest into yourself, your profession and your organization.
Many Chest Conferences have been organized throughout the year across the world and it has been noticed that “COPD” was the main topic of discussion.

Target Audience:

  •  Pulmonologists

  •  Academicians

  •  Research Scholars

  •  Professors

  •  Medical Students

  •  Practitioners

  •  Physicians

  •  Nurses

  •  Clinical Researchers

  •  Business Entrepreneurs

  •  Software Developing Companies

  •  Medical Devices Companies

  •  Biomedical Companies

  •  Biotechnology Companies

  •  Data Management Companies

  •  Other Healthcare Professionals with an interest in COPD

Sessions / Tracks

Track 1: Lung and its Functions
Lungs are the primary organs of respiration in humans and many other animals. Lungs are sack of tissue located just below the rib cage and above the diaphragm. The lungs are a pair of organs that are responsible for the exchange of oxygen and carbon dioxide between the air and blood. The exchange of the air between the lungs and blood are through the arterial and venous system. Arteries and veins both carry and move blood throughout the body, but the process for each is very different. The lungs are a pair of cone-shaped, spongy, pinkish-grey tissue and air-filled organs. The trachea conducts inhaled air into the lungs through its tubular branches called bronchi. In the lungs, the main stem bronchi divide into smaller bronchi and then into even smaller tubes called bronchioles. Bronchioles end in cluster of tiny air sacs called alveoli. Breathing becomes more challenging in chronic obstructive lung disease due to excess mucus and also degeneration of the lungs. The bronchioles become inflamed and narrower in COPD patient.

Track 2: Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term used to describe obstructive lung diseases including emphysema, chronic bronchitis, refractory asthma, and some forms of bronchiectasis. This disease is characterized by shortness of breath and cough with sputum production. Emphysema is a common type of COPD that primarily causes shortness of breath due to over- inflation of the air sacs in the lung. Damage in this area makes it problematic for people with emphysema to expel air from their lungs. This leads to a build-up of carbon dioxide in the body and a countless number of emphysema signs and symptoms. Chronic Bronchitis causes irritation and inflammation of the bronchial tubes, the airway that carry air to lungs. When the air tubes are inflamed and irritated, thick mucus starts forming in tubes. Over time, this mucus plugs up airways and difficulty in breath starts. When you cough this mucus up, the discharges are known as sputum, or phlegm. Asthma COPD Overlap Syndrome (ACOS) occurs when eosinophilic bronchial and systemic inflammation, reversible airflow obstruction, and increased response to inhaled corticosteroids, compared with COPD patients. Wheezing, coughing, chest tightness and shortness of breath are some of the symptoms.

Track 3: COPD: Sign and Symptoms
COPD symptoms can be typical and non-typical type; the mainly seen symptoms are prolonged cough, sputum production and shortness of breath. These symptoms are available for a delayed time frame and regularly intensify with time. An ongoing cough or a cough that produces a lot of mucus, shortness of breath; especially during physical activities or exercises, wheezing; a whistling or squeaky sound when person breath can be heard on examination with a stethoscope, tightness in chest, cyanosis; blueness of the lips or fingernails beds are the some common symptoms which can be seen in COPD. Serious COPD can bring about different side effects, for example, lack of energy, swelling in your ankles, feet, or legs; weight loss or underweight; and lower muscle endurance. The seriousness of your indications will rely on how much lung damage you have. If you continue smoking, the damage will happen quicker than if you stop smoking.

Track 4: Cause of COPD
COPD is characterized by thickening of the airways and limitation to airflow. People with COPD have trouble breathing and shortness of breath. It is stated by the Global Initiative for Chronic Obstructive Lung Disease as “a preventable and treatable disease.. characterized by airflow limitation that is not fully reversible”. The primary cause of COPD is smoking; tobacco smoke, marijuana, cigar and water pipe smoke. The risk of COPD increases in child when women smoke during pregnancy. Serious and delayed introduction to workplace dust, chemicals and fumes increment the danger of COPD in both smokers and nonsmokers. Sometimes, a genetic condition called alpha-1 antitrypsin deficiency may play a role in causing COPD. People have low levels of alpha-1 antitrypsin (AAT); a protein made in the liver, can have this disease.

Track 5: Pathophysiology of COPD
The paradigm for the pathogenesis of COPD is that constant airflow restriction comes about because of an abnormal inflammatory reaction to breathed in particles and gasses in the lung. Airspace inflammation appears to be diverse in vulnerable smokers and Chronic Inflammation includes a power of breathed in aggravations, for example, CD8+ T lymphocytes, neutrophils, and macrophages, B cells and macrophages to gather. Whenever activated, these cells start a inflammatory cascade that triggers the arrival of inflammatory mediators for example, tumor necrosis factor alpha (TNF-?), and prompts to structural changes. Airway rebuilding in COPD is an immediate consequence of the inflammatory response related with COPD and prompts to narrowing of the airways. Three primary elements add to this: peril bronchial fibrosis, develop of scar tissue and Infection control from damage to the airway and over-multiplication of the epithelial cells covering the airway. Parenchymal obliteration is related with loss of lung tissue flexibility and interstitial lung illness, which happens accordingly of decimation of the structures supporting and nourishing the alveoli. This implies the little airway crumple amid exhalation, hindering airflow, trapping air in the lungs and decreasing lung limit.

Track 6: COPD and Co-morbidities
Comorbidities such as coronary artery disease, diabetes mellitus, osteoporosis, hypertension and muscle weakness are commonly seen in the person with Chronic obstructive pulmonary disease (COPD), but their prevalence varies tremendously. Tobacco smoking is a common risk factor for many of these comorbidities and for COPD, making it tough to draw conclusions about the relationship between COPD and these comorbidities including Lung Cancer. Pneumonia occurs when bacteria enter the lungs; which can weaken the lungs by creating an infection. This can lead to continuous illness and this downward spiral can lead to a rapid deterioration of health in COPD patient. Respiratory Insufficiency is an important complication of Chronic obstructive pulmonary disease.

Track 7: COPD Diagnosis and Diagnostics
Patient clinical history and physical examination should help to determine the possible cause and site of respiratory disease. After the results of physical examination, patients are suggested to undergo Lung function tests, Spirometry, Chest X-ray, CT scan, Arterial blood gas analysis and other laboratory tests based upon patient condition. Lung function tests measure the amount of air patient breathe in and out, and if your lungs are delivering enough oxygen to your blood. Spirometry measures the amount of airflow obstruction present and is generally done after the use of a bronchodilator, a medication to open up the airways. A Chest X-ray or Chest CT scan and complete blood count may be helpful to exclude other conditions at the time of diagnosis. An Arterial blood gas test measures the oxygen level in blood and the result can show how severe COPD is and whether patient need oxygen therapy. Transthoracic ultrasonography is a sensitive diagnostic tool for pleural disease (eg; pleural effusion, pneumothorax) and for parenchymal lung disease when lesions are adjacent to the pleural surface.

Track 8: COPD Epidemiology
COPD Epidemiology is the review and investigation of the examples, causes, and impacts of Chronic obstructive pulmonary disease in characterized populaces. According to the World Health Organization, COPD is the fourth foremost cause of death in the world, with almost 2.75 million deaths per annum, or 4.8% of deaths. In France, the mortality rate is approximately 40 deaths per 100,000 populations. At one time, COPD was more regular in men, but since of expanded tobacco use among ladies in high-wage nations and the higher danger of introduction to indoor air contamination in low-wage nations, the malady now influences men and ladies similarly.

Track 9: Advancement in Lung surgeries
Surgery is needed to take biopsies (tissue samples) of the lung for diagnosis. Recent advances in optic/video systems and endoscopic operating instruments have made thoracoscopic easier and more accurate than previous years. The operative mortality rate has decreased (1%) and the diagnostic accuracy has increased (99%).
Thoracoscopy has been done at an increasing frequency in recent years because of its wide applications, especially in the areas of therapeutic or operative procedures such as carbon dioxide laser treatment of spontaneous pneumothorax or diffuse bullous emphysema and Lung volume reduction and also in the treatment of various airway diseases. Two common ways to do surgery on your lungs are thoracotomy and video-assisted thoracoscopic surgery (VATS). It involves passing a telescopic camera through small cuts in the chest to examine the lungs or pleura (linings of the lung) under video guidance and also associated with lung transplantation.

Track 10: COPD Prevention
Patients with COPD, faces difficulty in clearing their lungs; with bacteria, dusts and other pollutants presents in surrounding environment. Self-Management mediation help patients with Chronic obstructive pulmonary disease (COPD) procure and hone the aptitudes they have to do disease specific medical regimens, direct changes in well being conduct and provide enthusiastic support to enable patients to control their disease. Previously, acute toxicity was associated with occupational exposures to concentrations of soluble beryllium salts greater than 100 ?g/m3. With the start of industrial control measures to minimize air levels, acute pulmonary syndromes have virtually disappeared in respective to COPD. Smoking bans in public areas and places of work are important measures to decrease exposure to secondhand smoke. Usage of proper stove and chimneys may improve indoor air quality by 85%, by using alternative energy sources. Powerful dust control can be accomplished by enhancing ventilation, utilizing water sprays and by utilizing mining strategies that minimize dust generation.


Track 11:
COPD and Lung Cancer
Both
COPD
and lung cancer are major global health concerns owing to cigarette smoking, and represent a vast, global, preventable disease problem. Patients with COPD are at high risk for both the development of primary lung cancer, as well as poor result after lung cancer diagnosis and treatment. As a result of existing impairments in lung function, patients with COPD frequently do not meet traditional criteria for tolerance of definitive surgical lung cancer therapy. The risk of lung cancer in patients with COPD is two to five fold greater when compared with smokers without COPD. On the other hand COPD could be a driving factor in lung cancer, by increasing oxidative stress and the resulting DNA damage, chronic exposure to pro-inflammatory cytokines, repression of the DNA repair mechanisms and increased cellular proliferation. Understanding the mechanisms that drive these processes in primary cells from patients with these diseases along with better disease models is fundamental for the advancement of new treatments.

Market Analysis

Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term used to describe obstructive lung diseases including emphysema, chronic bronchitis, refractory asthma and some forms of bronchiectasis. This disease is characterized by shortness of breath and cough with sputum production.

Importance & Scope
COPD Congress 2017 will be the best platform for all the Pulmonologists, Academicians, Research Scholars, Professors, Medical Students who are working in this field to exchange their knowledge related to COPD & Pulmonology Research. This international event is an effort to understand the underlying biological procedures which are amended to increase effectiveness, precision, survivability and quality of life.
Specialists will clarify how another era of treatment alternatives gives patients new trust in the battle against COPD.
Geologically, the worldwide COPD research market is grouped mainly at; United Kingdom, Netherlands, United States, Austria, Germany, Europe, Asia-Pacific, Middle East, Japan, and Africa. 

Why Vienna?
Vienna is the capital and biggest city of Austria and one of the nine states of Austria. Vienna is situated in the eastern part of Austria and is near the fringes of the Czech Republic, Slovakia, and Hungary. Vienna is Austria's primary city, with around 1.8 million populations, and its cultural, economic, and political center. It is the seventh largest city by population inside city restrains in the European Union. Vienna has the second largest number of German speakers after Berlin. Vienna is host to many major international organizations, including the United Nations and OPEC. Vienna is also known as “The City of Dreams” and “City of Music”; as a result of its music legacy. The Economist Intelligence Unit ranked Vienna first in its annual "Quality of Living" survey of hundreds of cities around the world.

Conference Highlights

  • Chest
  • Lung and its Functions
  • Chronic Obstructive Pulmonary Disease
  • COPD: Sign and Symptoms
  • Cause of COPD
  • Pathophysiology of COPD
  • COPD and Co-morbidities
  • COPD Diagnosis and Diagnostics
  • COPD Epidemiology
  • Advancement in Lung Surgeries
  • COPD Prevention and Management
  • COPD and Lung Cancer
  • Genetics of COPD
  • Therapies for COPD
  • COPD Exacerbation
  • Depression and Anxiety in COPD
  • COPD Health Care
  • COPD Complications
  • Drugs Acting on COPD

Why to attend COPD Congress 2017??
COPD Congress 2017 gives an exciting opportunity to meet with like-minded individuals and industry peers. Congress unites individuals from all different geographical areas who share a common discipline or field. Congress gives you the opportunity to converse with these individuals one-on-one about what they are really going after, and they may even give you guidance on how to enhance your own particular work. At conference you have the opportunity to get feedback on your work from individuals who have never seen it before and may provide new insight. Briefly it is an invest into yourself, your profession and your organization.

Target Audience

COPD Congress 2017 welcomes the Pulmonologists, Academicians, Research Scholars, Professors, Medical Students, Practitioners, Physicians, Nurses, Clinical Researchers, Business Entrepreneurs, Software Developing Companies, Medical Devices Companies, Biomedical Companies, Biotechnology Companies, Data Management Companies and Other Healthcare Professionals with an interest in COPD to be a part of it.

Major COPD Research Associations
American Academy Of Allergy, Asthma & Immunology
American Association For Respiratory Care
Allergy/Asthma Information Association
American Lung Association
American Thoracic Society
Asian Pacific Society Of Respirology
Association Argentina De Medicina Respiratoria
Australian Lung Foundation
Association Of Bulgarians With Bronchial Asthma (Abba)
Asthma Society Of Canada
Asthma and Allergy Foundation of America
Asthma UK
Asthma and Allergy Association
Asthma Australia
Asthma and Respiratory Foundation NZ
Breathe The Lung Association
British Lung Foundation
British Thoracic Society
Canadian Thoracic Society
Chest Foundation
Chinese COPD Patient Education Organization
COPD Canada
COPD Foundation
COPD Thoracic Society
COPD - Alert Support And Advocacy Group
COPD - International
COPD Patient Organization Of Vietnam
COPD Patients Club Kyrgyzstan
COPD Club Of Northern Thailand
COPD Patient Organization Of Vietnam
COPD Patients Club Kyrgyzstan
European Respiratory Society
European Lung Foundation
Emphysema Foundation For Our Right To Survive
Global Initiative For Chronic Obstructive Lung Disease
Infectious Diseases Society Of America
Irish Thoracic Society
Lung Cancer Europe
Lung Foundation Australia
National Emphysema Foundation
National Lung Health Education Program
National Heart, Lung And Blood Institute, National Institutes Of Health
Ontario Lung Association
Pulmonary Fibrosis Foundation
Pulmonary Fibrosis UK
Pulmonary Education &Research Foundation
Pulmonary Hypertension Association
Respiratory Health Association
The National Asthma Council Australia
The Canadian Lung Association
The International Association For The Study Of Lung Cancer


Major Universities
Australian National University, Australia
Charles Darwin University Casoria, Australia
Columbia University Medical  Center, United States
Curtin University Bentley, Australia
Dar Al Uloom University, Saudi Arabia
Harvard University, United States
Imperial College London, United Kingdom
Iqbal Chest Centre, Bangladesh
Johns Hopkins University, Maryland
Leiden University, Netherlands
Linnaeus University, Sweden
Maastricht University, Netherlands
Macquarie University, Australia
McGill University, Canada
Medi7 Bent Leigh, Australia
Tufts University, United States
University of Birmingham, United Kingdom
University of California, San Francisco
University  of California Los Angeles, United States
University of Colorado Boulder, United States
University of Groningen, Netherlands
University of Pittsburgh, Pennsylvania
University of Toronto, Canada
University of Washington, United States


Major Companies
Abbott Laboratories, US
Allergan Pharmaceutical, US
Almirall, Spain
Amgen Pharmaceutical, US
Amphastar Pharmaceuticals Inc.
AstraZeneca, Switzerland
Bayer, Germany
Beacon Pharmaceuticals Ltd, UK
Biotie Therapies, Finland
Boehringer Ingelheim Pharmaceut Inc., Germany
Chiesi Pharmaceutical, Italy
Cipla Limited, India
Cohero Health, US
Forest Laboratories, US
Gecko Health, US
GlaxoSmithKline Pharmaceutical, UK
North Carolina Biotechnology Center, England
Novartis International AG, Switzerland
Panmira Pharmaceuticals LLC
Pearl Therapeutics Inc.
PhRMA, America
Pfizer, US
Probiomics Ltd., Australia
Roche Holding AG, Switzerland
Sunovion, US
Vectura Group, UK


Market Analysis Report
Worldwide COPD market is measured to as of now be worth $11.3 billion, and is estimate to achieve an estimation of $15.6 billion by 2019. A current market research concentrate distributed by Transparency Market Research (TMR), the international asthma and COPD market was worth USD 25,102.3 million in 2010, which is relied upon to achieve USD 26,965.5 million in 2017 alongside a CAGR figure of 1.03% over the estimated by 2017.
According to a survey done by WHO; Chronic obstructive pulmonary disease will be the third leading cause of death world-wide causing considerable health costs, in 2020. 
Globally, it is assessed that 3 million deaths were caused by the COPD in 2015 (that is, 5% of all deaths comprehensively in that year). Over 90% of COPD deaths happen in low and middle-income countries.
In the coming five years, the global asthma and COPD medicate market is relied upon to develop gradually and immovable. In 2010, the asthma tranquilize section commanded the general asthma and COPD advertise at USD 14,509.1 million. A lot of this development will be driven by a high number of new, more viable and advantageous items entering the market and telling more notable esteem contrasted with the treatments as of now in the market.
The asthma and COPD Therapies Market 2015-2025 report examines the current and future pharmaceutical treatments for these two respiratory diseases. With detailed numbers for both asthma and COPD indicating development everywhere throughout the world, understanding the market and the medications accessible is essential for each one of those in fields identified with the division. Presently, North America drives the worldwide market for asthma and COPD medications and gadgets. North America was trailed by Europe as far as market capitalization. Be that as it may, North America and Europe is relied upon to miss out a portion of the piece of the overall industry to other rising local markets inferable from the expiry of a few patens of pharmaceutical organizations working in these areas.

 


 

To Collaborate Scientific Professionals around the World

Conference Date November 6-7, 2017
Speaker Oppurtunity
Poster Oppurtunity Available
e-Poster Oppurtunity Available
Join The Discussion

Mail us at

For General Queries
copd@alliedconferences.org
For Registration
copdconference@alliedconferences.org
More details about sponsorship:sponsors@alliedacademies.com
Copyright © 2017-2018 Allied Academies, All Rights Reserved.